DOCSLIB.ORG

Glutamate Receptor Ion Channels: Structure, Regulation, and Function Stephen Traynelis, Emory University Lonnie P

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glutamate Receptor Ion Channels: Structure, Regulation, and Function Stephen Traynelis, Emory University Lonnie P Glutamate Receptor Ion Channels: Structure, Regulation, and Function Stephen Traynelis, Emory University Lonnie P. Wollmuth, SUNY Stony Brook Chris J. McBain, Eunice Kennedy Shriver Natl Inst Child Hlth & Hum Frank S. Menniti, CyclicM LLC Katie M. Vance, Emory University Kevin K. Ogden, Emory University Kasper B. Hansen, Emory University Hongjie Yuan, Emory University Scott J. Myers, Emory University Raymond Dingledine, Emory University Journal Title: Pharmacological Reviews Volume: Volume 62, Number 3 Publisher: American Society for Pharmacology and Experimental Therapeutics (ASPET) | 2010-09-01, Pages 405-496 Type of Work: Article | Final Publisher PDF Publisher DOI: 10.1124/pr.109.002451 Permanent URL: https://pid.emory.edu/ark:/25593/tws3d Final published version: http://dx.doi.org/10.1124/pr.109.002451 Copyright information: U.S. Government work not protected by U.S. copyright Accessed September 23, 2021 7:10 AM EDT Glutamate Receptor Ion Channels: Structure, Regulation, and Function Stephen Traynelis, Emory University Lonnie P. Wollmuth, Stony Brook University Chris J. McBain, Eunice Kennedy Shriver National Institute of Child Health and Human Development Frank S. Menniti, cyclicM LLC Katie M. Vance, Emory University Kevin K. Ogden, Emory University Kasper B. Hansen, Emory University Hongjie Yuan, Emory University Scott J. Myers, Emory University Raymond J Dingledine, Emory University Journal Title: Pharmacological Reviews Volume: Volume 62, Number 3 Publisher: American Society for Pharmacology and Experimental Therapeutics (ASPET) | 2010-09, Pages 405-496 Type of Work: Article | Final Publisher PDF Publisher DOI: 10.1124/pr.109.002451 Permanent URL: http://pid.emory.edu/ark:/25593/f867k Final published version: http://pharmrev.aspetjournals.org/content/62/3/405 Copyright information: U.S. Government work not protected by U.S. copyright Accessed September 18, 2019 3:54 PM EDT 0031-6997/10/6203-405–496$20.00 PHARMACOLOGICAL REVIEWS Vol. 62, No. 3 U.S. Government work not protected by U.S. copyright 2451/3592788 Pharmacol Rev 62:405–496, 2010 Printed in U.S.A. ASSOCIATE EDITOR: DAVID SIBLEY Glutamate Receptor Ion Channels: Structure, Regulation, and Function Stephen F. Traynelis, Lonnie P. Wollmuth, Chris J. McBain, Frank S. Menniti,1 Katie M. Vance, Kevin K. Ogden, Kasper B. Hansen, Hongjie Yuan, Scott J. Myers, and Ray Dingledine Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (S.F.T., K.M.V., K.K.O., K.B.H., H.Y., S.J.M., R.D.); Department of Neurobiology and Behavior & Center for Nervous System Disorders, Stony Brook University, Stony Brook, New York (L.P.W.); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland (C.J.M.); and cyclicM LLC, Mystic, Connecticut (F.S.M.) Abstract ................................................................................ 406 I. Introduction and nomenclature ........................................................... 407 II. Structure ............................................................................... 407 A. Subunit organization and quaternary structure ......................................... 407 B. Subunit stoichiometry ................................................................ 409 C. Receptor assembly and trafficking ..................................................... 411 D. The extracellular ligand binding domain................................................ 412 E. The extracellular amino-terminal domain ............................................... 414 F. The transmembrane domain........................................................... 415 G. The intracellular carboxyl-terminal domain and protein binding partners .................. 415 H. Transmembrane ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor regulatory proteins and other auxiliary subunits ........................................ 418 III. Regulation of transcription and translation................................................. 419 A. ␣-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors .......................... 419 1. Gria1............................................................................. 419 2. Gria2............................................................................. 420 3. Gria3 and Gria4................................................................... 421 B. Kainate receptors Grik1 to Grik5 ...................................................... 421 C. N-Methyl-D-aspartate receptors ........................................................ 421 1. Grin1 ............................................................................ 421 2. Grin2a ........................................................................... 422 3. Grin2b ........................................................................... 422 4. Grin2c, Grin2d, Grin3a, and Grin3b ................................................. 423 D. Translational control of glutamate receptors ............................................ 424 IV. Post-translational regulation.............................................................. 425 A. ␣-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate receptor phosphorylation ...................................................................... 425 B. N-Methyl-D-aspartate and ␦ receptor phosphorylation .................................... 427 C. Other post-translational modifications of glutamate receptors............................. 429 D. Proteolysis of glutamate receptors...................................................... 430 V. Agonist and antagonist pharmacology ..................................................... 431 A. ␣-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, kainate, and ␦ receptor agonists ..... 431 B. N-Methyl-D-aspartate receptor agonists................................................. 434 C. ␣-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate receptor competitive antagonists .......................................................................... 437 D. N-Methyl-D-aspartate receptor competitive antagonists .................................. 439 Address correspondence to: Dr. Stephen Traynelis, Dept Pharmacology, Emory University School of Medicine, Rollins Research Center, 1510 Clifton Road, Atlanta GA 30322-3090. E-mail: [email protected] 1Current affiliation: Mnemosyne Pharmaceuticals, Inc., Providence, Rhode Island. This article is available online at http://pharmrev.aspetjournals.org. doi:10.1124/pr.109.002451. 405 406 TRAYNELIS ET AL. E. Noncompetitive antagonists ........................................................... 440 F. Uncompetitive antagonists ............................................................ 443 VI. Allosteric regulation ..................................................................... 445 A. Positive and negative allosteric modulators ............................................. 445 B. Divalent ions ........................................................................ 447 C. Monovalent ions...................................................................... 448 D. Protons.............................................................................. 449 E. Polyamines .......................................................................... 449 F. Neurosteroids ........................................................................ 450 G. Fatty acids .......................................................................... 450 H. Other allosteric modulators ........................................................... 450 VII. Molecular determinants of gating ......................................................... 450 A. Time course of glutamate receptor activation and deactivation ............................ 450 B. Mechanisms linking agonist binding to channel gating ................................... 451 C. Molecular determinants and mechanisms of partial agonism.............................. 453 D. Molecular determinants and mechanisms of gating ...................................... 455 E. Molecular determinants of desensitization .............................................. 457 VIII. Molecular determinants of ion permeation and block ........................................ 458 A. Nature of the ion permeation pathway ................................................. 458 B. Mechanisms of ion permeation......................................................... 460 C. Voltage-dependent channel block by endogenous ions .................................... 462 IX. Role in synaptic function and plasticity .................................................... 463 A. Synaptic ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors .................. 463 B. Synaptic kainate receptors ............................................................ 464 C. Synaptic and extrasynaptic N-Methyl-D-aspartate receptors .............................. 465 D. Synaptic plasticity.................................................................... 466 1. N-Methyl-D-aspartate receptors ..................................................... 466 2. ␣-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors ....................... 467 X. Therapeutic potential .................................................................... 467 A. Glutamate receptor antagonists and the prevention of acute neuronal death ............... 467 B. The next generation ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate receptor antagonists .................................................................
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Ligand-Gated Ion Channels' British Journal of Pharmacology, Vol
    Edinburgh Research Explorer The Concise Guide to PHARMACOLOGY 2015/16 Citation for published version: Alexander, SP, Peters, JA, Kelly, E, Marrion, N, Benson, HE, Faccenda, E, Pawson, AJ, Sharman, JL, Southan, C, Davies, JA & CGTP Collaborators 2015, 'The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels' British Journal of Pharmacology, vol. 172, no. 24, pp. 5870-5903. DOI: 10.1111/bph.13350 Digital Object Identifier (DOI): 10.1111/bph.13350 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: British Journal of Pharmacology General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 05. Apr. 2019 S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels. British Journal of Pharmacology (2015) 172, 5870–5903 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Ligand-gated ion channels Stephen PH Alexander1,
    [Show full text]
  • Mouse Anti-Human GRID2 Monoclonal Antibody, Clone 2B2 (CABT-B10363) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Mouse anti-Human GRID2 monoclonal antibody, clone 2B2 (CABT-B10363) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Immunogen GRID2 (NP_001501, 908 a.a. ~ 1008 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Isotype IgG1 Source/Host Mouse Species Reactivity Human Clone 2B2 Conjugate Unconjugated Applications WB,sELISA,ELISA Sequence Similarities DTLPTRQALEQISDFRNTHITTTTFIPEQIQTLSRTLSAKAASGFTFGNVPEHRTGPFRHRAPNGG FFRSPIKTMSSIPYQPTPTLGLNLGNDPDRGTSI* Format Liquid Size 100 μg Buffer In 1x PBS, pH 7.2 Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. BACKGROUND Introduction The protein encoded by this gene is a member of the family of ionotropic glutamate receptors which are the predominant excitatory neurotransmitter receptors in the mammalian brain. The encoded protein is a multi-pass membrane protein that is expressed selectively in cerebellar Purkinje cells. A point mutation in the mouse ortholog, associated with the phenotype named lurcher, in the heterozygous state leads to ataxia resulting from selective, cell-autonomous apoptosis of cerebellar Purkinje cells during postnatal development. Mice homozygous for this mutation die shortly after birth from massive loss of mid- and hindbrain neurons during late 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved embryogenesis. This protein also plays a role in synapse
    [Show full text]
  • The Role of Diallyl Thiosulfinate Associated with Nuciferine And
    Cai_Stesura Seveso 27/03/18 09:29 Pagina 59 DOI: 10.4081/aiua.2018.1.59 ORIGINAL PAPER The role of diallyl thiosulfinate associated with nuciferine and diosgenin in the treatment of premature ejaculation: A pilot study Tommaso Cai 1, Andrea Cocci 2, Giamartino Cito 2, Bruno Giammusso 3, Alessandro Zucchi 4, Francesco Chiancone 5, Maurizio Carrino 5, Francesco Mastroeni 6, Francesco Comerci 7, Giorgio Franco 8, Alessandro Palmieri 9 1 Department of Urology, Santa Chiara Regional Hospital, Trento, Italy; 2 Department of Urology, University of Florence, Florence, Italy; 3 Department of Andrology, Policlinico Morgagni, Catania, Italy; 4 Department of Urology, University of Perugia, Perugia, Italy; 5 Department of Urology, Cardarelli Hospital, Naples, Italy; 6 Department of Urology, Azienda Ospedaliera Papardo, Messina, Italy 7 Urologist, Bologna, Italy; 8 Department of Urology, Sapienza University of Rome, Rome, Italy; 9 Department of Urology, University of Naples, Federico II, Naples, Italy. Summary Objective: To assess the efficacy and safety with prevalence rates of 20-30%, probably affecting of an association of diallyl thiosulfinate with every man at some point in his life (2, 3). It may result nuciferine and diosgenin in the treatment of a group of patients in unsatisfactory sexual intercourse for both partners, suffering from premature ejaculation (PE), primary or second- decreasing sexual self-confidence and self-esteem and ary to erectile dysfunction (ED). resulting in an overall reduction of quality of life (QoL) Materials and methods: From July 2015 to October 2016, 143 (4). Lifelong PE occurs within 30-60 seconds after vagi- patients (mean age 25.3; range 18-39) affected by PE complet- ed the study and were finally analyzed in this phase I study.
    [Show full text]
  • Supplemental Information
    Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig.
    [Show full text]
  • Identification of Key Genes and Pathways Involved in Response To
    Deng et al. Biol Res (2018) 51:25 https://doi.org/10.1186/s40659-018-0174-7 Biological Research RESEARCH ARTICLE Open Access Identifcation of key genes and pathways involved in response to pain in goat and sheep by transcriptome sequencing Xiuling Deng1,2†, Dong Wang3†, Shenyuan Wang1, Haisheng Wang2 and Huanmin Zhou1* Abstract Purpose: This aim of this study was to investigate the key genes and pathways involved in the response to pain in goat and sheep by transcriptome sequencing. Methods: Chronic pain was induced with the injection of the complete Freund’s adjuvant (CFA) in sheep and goats. The animals were divided into four groups: CFA-treated sheep, control sheep, CFA-treated goat, and control goat groups (n 3 in each group). The dorsal root ganglions of these animals were isolated and used for the construction of a cDNA= library and transcriptome sequencing. Diferentially expressed genes (DEGs) were identifed in CFA-induced sheep and goats and gene ontology (GO) enrichment analysis was performed. Results: In total, 1748 and 2441 DEGs were identifed in CFA-treated goat and sheep, respectively. The DEGs identi- fed in CFA-treated goats, such as C-C motif chemokine ligand 27 (CCL27), glutamate receptor 2 (GRIA2), and sodium voltage-gated channel alpha subunit 3 (SCN3A), were mainly enriched in GO functions associated with N-methyl- D-aspartate (NMDA) receptor, infammatory response, and immune response. The DEGs identifed in CFA-treated sheep, such as gamma-aminobutyric acid (GABA)-related DEGs (gamma-aminobutyric acid type A receptor gamma 3 subunit [GABRG3], GABRB2, and GABRB1), SCN9A, and transient receptor potential cation channel subfamily V member 1 (TRPV1), were mainly enriched in GO functions related to neuroactive ligand-receptor interaction, NMDA receptor, and defense response.
    [Show full text]
  • Preferred Drug List 4-Tier
    Preferred Drug List 4-Tier 21NVHPN13628 Four-Tier Base Drug Benefit Guide Introduction As a member of a health plan that includes outpatient prescription drug coverage, you have access to a wide range of effective and affordable medications. The health plan utilizes a Preferred Drug List (PDL) (also known as a drug formulary) as a tool to guide providers to prescribe clinically sound yet cost-effective drugs. This list was established to give you access to the prescription drugs you need at a reasonable cost. Your out- of-pocket prescription cost is lower when you use preferred medications. Please refer to your Prescription Drug Benefit Rider or Evidence of Coverage for specific pharmacy benefit information. The PDL is a list of FDA-approved generic and brand name medications recommended for use by your health plan. The list is developed and maintained by a Pharmacy and Therapeutics (P&T) Committee comprised of actively practicing primary care and specialty physicians, pharmacists and other healthcare professionals. Patient needs, scientific data, drug effectiveness, availability of drug alternatives currently on the PDL and cost are all considerations in selecting "preferred" medications. Due to the number of drugs on the market and the continuous introduction of new drugs, the PDL is a dynamic and routinely updated document screened regularly to ensure that it remains a clinically sound tool for our providers. Reading the Drug Benefit Guide Benefits for Covered Drugs obtained at a Designated Plan Pharmacy are payable according to the applicable benefit tiers described below, subject to your obtaining any required Prior Authorization or meeting any applicable Step Therapy requirement.
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • GRID2 and Spinocerebellar Ataxia
    Missense variants as a possible cause of GRID2-related spinocerebellar ataxia type 18 M. Calvo1, D. Trujillano1, N. Nahavandi1, A. Rolfs1,2, M. Tarnopolsky3, R. Abou Jamra1 1Centogene AG, Rostock, Germany 2Albrecht-Kossel-Institute for Neuroregeneration, Medical University Rostock, Rostock, Germany 3Department of Pediatrics, McMaster University, Hamilton, ON, Canada Summary Whole Exome Sequencing (WES) revealed in a Canadian patient with early-onset episodic ataxia, developmental delay, and further symptoms, two in trans missense variants in the GRID2 gene: c.2128C>T (Arg170Trp) and c.2218G>A (p.Val740Ile). GRID2 has been recently associated with spinocerebellar ataxia type 18. Based on the recent literature, our results suggest that at least one of the variants detected, c.2128C>T (Arg170Trp), could be associated with the patient´s phenotype due to its low frequency and its location in a conserved amino acid position. Clinical information • Female patient of Canadian origin • Since the age of 8 months the patient showed episodic ataxia, failure to thrive, developmental delay, dystonic posturing and seizures. • At the age of 12 years, the patient shows in addition progressive cerebellar atrophy and nystagmus. WES Technology at Centogene: CentoXome® raw reads • Full list of variants 60K 73479 variants in this case • Exonic and splice 13K plicons 293.903 Analysis statistics ~3K • Non-synonymous and splicing Number of mapped reads 39.327.751 Percent reads on target 95,35% • Only rare variants (MAF<1%) Average reads per amplicon150 127,6 with at leastNumber of amplicons 20 reads293.903 Average reads per amplicon 127,6 8 • Only segregating Amplicons with at least 20 reads 93,66% • Top based on MAF and in silico93,66% parameters 2 GRID2 gene 1 • Top based on function of gene and literature GRID2 and spinocerebellar ataxia • GRID2 (chromosome 4q22) encodes a glutamate receptor that is thought to be selectively expressed in the Purkinje cells of the cerebellum.
    [Show full text]
  • Mechanisms of Addiction
    Mechanisms of Addiction Prof David Nutt, FMedSci Centre for Neuropsychopharmacology, Division of Brain Sciences, Burlington Danes Building, Imperial College London, London W12 0NN, UK. [email protected] www.tocris.com What is addiction? Although the term addiction is controversial because it can be stigmatizing and divisive, we use it here as a useful shorthand for the processes by which people become dependent on the use of drugs, or activities such as gambling, to the point where it distorts and even takes over their lives. The key feature of drug addiction is the inability to stop using the drug despite clear evidence of harm; the drug becomes progressively more important, dominating life at the expense of family, friends and work. Not all those who use drugs become addicted and factors that predispose to addiction include the class of drug, family history of addiction and propensity to withdrawal reactions and craving. Using drugs to deal with psychiatric problems is particularly likely to lead to addiction. Brain Circuits Associated with Addiction Classes of Addictive Drugs Products available from Tocris Stimulants Stimulants are drugs that act by releasing dopamine and, D Cocaine, (D)-Amphetamine sulfate, 3 Morphine, Mephedrone, in some cases, blocking its reuptake. This class includes Threo-methylphenidate D cocaine (and crack), amphetamine and its derivatives such 1,5 MAO as metamphetamine (crystal meth) and methylphenidate, + ATP (R)-(-)-Deprenyl, Moclobemide DA and some cathinones, such as mephedrone. Their actions DAT PFC AC are dependent on speed of brain penetration, with smoking cAMP PKA GBR 12909, Tetrabenazine, Reserpine, MAO VMAT and iv injection the most addictive routes, but are largely – (±)-MDMA CREB Dopamine D and D ACG unaffected by dopamine receptor antagonists.
    [Show full text]
  • CENTOGENE's Severe and Early Onset Disorder Gene List
    CENTOGENE’s severe and early onset disorder gene list USED IN PRENATAL WES ANALYSIS AND IDENTIFICATION OF “PATHOGENIC” AND “LIKELY PATHOGENIC” CENTOMD® VARIANTS IN NGS PRODUCTS The following gene list shows all genes assessed in prenatal WES tests or analysed for P/LP CentoMD® variants in NGS products after April 1st, 2020. For searching a single gene coverage, just use the search on www.centoportal.com AAAS, AARS1, AARS2, ABAT, ABCA12, ABCA3, ABCB11, ABCB4, ABCB7, ABCC6, ABCC8, ABCC9, ABCD1, ABCD4, ABHD12, ABHD5, ACACA, ACAD9, ACADM, ACADS, ACADVL, ACAN, ACAT1, ACE, ACO2, ACOX1, ACP5, ACSL4, ACTA1, ACTA2, ACTB, ACTG1, ACTL6B, ACTN2, ACVR2B, ACVRL1, ACY1, ADA, ADAM17, ADAMTS2, ADAMTSL2, ADAR, ADARB1, ADAT3, ADCY5, ADGRG1, ADGRG6, ADGRV1, ADK, ADNP, ADPRHL2, ADSL, AFF2, AFG3L2, AGA, AGK, AGL, AGPAT2, AGPS, AGRN, AGT, AGTPBP1, AGTR1, AGXT, AHCY, AHDC1, AHI1, AIFM1, AIMP1, AIPL1, AIRE, AK2, AKR1D1, AKT1, AKT2, AKT3, ALAD, ALDH18A1, ALDH1A3, ALDH3A2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDOA, ALDOB, ALG1, ALG11, ALG12, ALG13, ALG14, ALG2, ALG3, ALG6, ALG8, ALG9, ALMS1, ALOX12B, ALPL, ALS2, ALX3, ALX4, AMACR, AMER1, AMN, AMPD1, AMPD2, AMT, ANK2, ANK3, ANKH, ANKRD11, ANKS6, ANO10, ANO5, ANOS1, ANTXR1, ANTXR2, AP1B1, AP1S1, AP1S2, AP3B1, AP3B2, AP4B1, AP4E1, AP4M1, AP4S1, APC2, APTX, AR, ARCN1, ARFGEF2, ARG1, ARHGAP31, ARHGDIA, ARHGEF9, ARID1A, ARID1B, ARID2, ARL13B, ARL3, ARL6, ARL6IP1, ARMC4, ARMC9, ARSA, ARSB, ARSL, ARV1, ARX, ASAH1, ASCC1, ASH1L, ASL, ASNS, ASPA, ASPH, ASPM, ASS1, ASXL1, ASXL2, ASXL3, ATAD3A, ATCAY, ATIC, ATL1, ATM, ATOH7,
    [Show full text]
  • The Glutamate Receptor Ion Channels
    0031-6997/99/5101-0007$03.00/0 PHARMACOLOGICAL REVIEWS Vol. 51, No. 1 Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. The Glutamate Receptor Ion Channels RAYMOND DINGLEDINE,1 KARIN BORGES, DEREK BOWIE, AND STEPHEN F. TRAYNELIS Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia This paper is available online at http://www.pharmrev.org I. Introduction ............................................................................. 8 II. Gene families ............................................................................ 9 III. Receptor structure ...................................................................... 10 A. Transmembrane topology ............................................................. 10 B. Subunit stoichiometry ................................................................ 10 C. Ligand-binding sites located in a hinged clamshell-like gorge............................. 13 IV. RNA modifications that promote molecular diversity ....................................... 15 A. Alternative splicing .................................................................. 15 B. Editing of AMPA and kainate receptors ................................................ 17 V. Post-translational modifications .......................................................... 18 A. Phosphorylation of AMPA and kainate receptors ........................................ 18 B. Serine/threonine phosphorylation of NMDA receptors ..................................
    [Show full text]